Navigation Links
QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
Date:12/15/2008

Efficacy and Safety Study to Support Phase 3 Combination Rule Trial for NDA Submission

SYDNEY, Australia and BEDMINSTER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today initiation of a comparative study to evaluate the efficacy and safety profile of MoxDuoIR(TM) against equivalent analgesic doses of morphine and oxycodone alone for the treatment of acute moderate to severe pain. Data collected from this study will also be used to support final Phase 3 trials required for NDA submission. The Company expects to complete dosing prior to Q2 2009.

"While successful clinical trials to date have shown the potential of MoxDuo(TM) to provide equal or better analgesia with a reduction of total opioid dose and improved tolerability, this study is designed to provide direct evidence of enhanced efficacy when compared to equivalent analgesic doses of morphine and oxycodone alone," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Our goal is to demonstrate the clinical value and superiority of MoxDuoIR(TM) over its individual components in post-surgical acute pain relief."

The double-blind, randomized and repeated fixed-dose study compares MoxDuoIR's(TM) efficacy and safety to corresponding doses of oxycodone and morphine in patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy). The study is targeted to enroll 180 patients at 6 US clinical research sites.

The primary clinical endpoints for this study focus on pain relief and intensity scores of MoxDuoIR(TM) versus equivalent doses of morphine and oxycodone alone during the first 24 hours following surgery. Secondary endpoints include: (1) ef
'/>"/>

SOURCE QRxPharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
4. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
5. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
11. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will grow moderately through 2023 as the aging population, ... of dental biomaterials all spur procedure volumes. Growth will ... China and India ... within reach for a larger proportion of the population. ...
(Date:12/19/2014)... DALLAS , Dec. 18, 2014   ISN ... Health & Safety Performance Indicators publication series. ... hours of activity reported in 2013 within its online ... health and safety key performance indicator (KPI) statistics. ... Hiring Clients, U.S. publication is available in ...
(Date:12/17/2014)... 16, 2014 The Activated Carbon ... which is why IBISWorld updated its original industry research ... benefit from an intensified focus on environmental policy. Over ... emission standards for power plants and a range of ... IBISWorld Industry Analyst Sarah Kahn, “a range of downstream ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... MaxCyte, Inc., the pioneer,in scalable, high performance ... a Product Demonstration of the MaxCyte STX Scalable,Transfection ... PDT, at the,A/C/T Assays & Cellular Targets Conference ... Madhusudan Peshwa, Vice President of Research and,Development at ...
... Women,s Health Resource Center,s Breast Cancer Study Also ... Risk Factor for Breast Cancer, RED BANK, N.J., ... not-for-profit National Women,s Health Resource Center (NWHRC), the,nation,s leading ... their overall physical appearance are significantly less,likely to be ...
... 23 Though the new USP 797,regulations, which ... of following the new minimums has the potential ... Steven Wieczorek,Supervisor, Environmental Sciences, Microtest, Inc., Issued ... USP 797,establishes bi-annual environmental sampling and testing as ...
Cached Biology Technology:MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting 2Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 2Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 3New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors 2New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors 3
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... Resveratrol, a compound in grapes, displays antioxidant and ... researchers at the UT Health Science Center San Antonio ... beneficial health effects. Resveratrol stimulates the expression of ... store fat, the team found. Adiponectin has a wide ...
... The bacterium which causes acne (Propionibacterium acnes) will be the ... Peter Lambert of Aston University. As well as acne, this ... is often ignored at diagnosis. Why are we not more ... length of stomach upsets and boost the immune system: , ...
... study that relates global energy use to economic growth, ... finds strong correlations between these two measures both among ... the study,s authors to infer that energy use limits ... in energy supply will be required to meet the ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2Probiotics, prebiotics and biofuel-producing bacteria 2Study finds energy limits global economic growth 2
Multi-enzyme complex containing a wide range of carbohydrases, including arabanase, cellulase,b-glucanase, hemi-cellulase and xylanase Patent/trademark/license (electronic): A product of Novozyme Cor...
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: